«PARKINSON'S DISEASE» PROJECT

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's. It is age-associated. In developed countries, the prevalence of PD among the entire population is 0.3%, among people over 60 it is 1%, and in people over 80 the it increases up to 3%.

 

WHY THE PROJECT IS SO IMPORTANT AND RELEVANT?

The disease is age-associated. In developed countries, the prevalence of Parkinson's disease among the entire population is 0.3%, among people over 60 it is 1%, and in people over 80 the it increases up to 3%.

For example, PD affects about a million patients in the USA. Each year 60,000 new cases are diagnosed worldwide, 19,000 of them in the UK. The total direct and indirect expenses of PD treatment in the United States are estimated at $ 25 billion per year/ Those include treatment expenses, losses associated with disability and inability to work. The average cost of supporting therapy for PD patients is $ 2,500 per year. In Europe and Russia, the total expenses for the treatment of all PD patients are € 30 billion per year.

Keep in mind that the world's population is aging. According to UN, the world's population over 60 years equaled 841 million people in 2013, which is four times the population of the same age in 1950 (202 million people). By 2050, a population over 60 years will exceed 2 billion people.

This means that the number of patients with Parkinson's disease will double in 20 years. There is no doubt that the neuroprotective market will become one of the priority ones, and will grow in proportion to the increase in life expectancy.

 

HOW THE PROJECT SOLVES THE PROBLEM

The commonly recognized cause of the development of Parkinson disease is the death of dopaminergic neurons in the brain. This is caused by a cascade of complex pathophysiological mechanisms in the mitochondria of neurons (mitochondria are the energy units of cells). Bringing to the lowest terms, mitochondria have a specific protein alpha-synuclein (a-syn), which sticks together and destroys mitochondria. This leads to the neuron death. A small number of viable neurons are unable to produce the required amount of dopamine. This leads to the development and progression of Parkinson disease.

The new molecule called JM-20 causes effects in all areas of PD pathogenetic mechanisms. Its pharmacological mechanism is associated with the protection of mitochondria – in the form of prevention of α-synuclein aggregation (sticking).

 

© NEYROS Co., Ltd., 2021

Development и marketing - WebCanape